Avenda’s iQuest platform enables the future of personalized prostate cancer care by opening the door for more precise treatments that can improve the quality of life for patients.
CULVER CITY, Calif., Dec. 7, 2022 /PRNewswire/ — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, today announced its cancer management platform, iQuestTM, has received 510(k) clearance by the U.S. Food and Drug Administration (FDA).
iQuest combines existing patient-specific diagnostic information and deep-learning algorithms to create a tailored map of where cancer is within the prostate that for the first time will allow for more personalized, effective and precise treatments. The platform enables a physician to make decisions that consider the cancer extent rather than treating the whole organ. This information supports physicians and patients with treatment selection, planning, guidance, and follow-up.
“We are excited about the potential to unlock precision care in prostate cancer with iQuest, as it is a key enabling technology for focal therapy to be a reality for urologists and patients,” said Dr. Shyam Natarajan, co-founder and CEO of Avenda Health. “In order for a doctor to treat focally, they need to know where cancer is and the healthy tissue to avoid. This is vital information that iQuest now provides. This is a huge step forward in transforming the standard of care in prostate cancer and brings us that much closer to offering effective therapy that preserves quality of life to providers and patients across the U.S.”